Drug intelligence / Profile preview

IR780 + PLGA

Development stage
Preclinical
Modality
Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Intratumoral
01

Overview

IR780 + PLGA is a research-stage theragnostic nanoparticle platform consisting of the near-infrared (NIR) photosensitizer dye IR780 encapsulated within a biodegradable poly(lactic-co-glycolic acid) (PLGA) polymer matrix. This system is designed for dual-mode imaging and therapy, primarily utilizing photothermal therapy (PTT) and sonodynamic therapy (SDT). Upon excitation by NIR light (typically 808 nm) or ultrasound, the IR780 component generates heat or reactive oxygen species (ROS) to induce tumor cell death or eliminate bacterial infections. The PLGA shell enhances the stability and biocompatibility of the hydrophobic IR780 dye, allowing for controlled release and improved tumor accumulation. While extensively studied in academic settings for indications such as breast cancer, hepatocellular carcinoma, and multidrug-resistant infections, it is not currently associated with a commercial pharmaceutical developer.

Other names
IR780-loaded PLGA nanoparticlesIR-780-loaded PLGA nanoparticlesIR 780-loaded PLGA nanoparticlesIR780/PLGA NPsIR780-PLGAIR-780-PLGAIR 780-PLGA
02

Targets

FOLR1 (FRα)NCL (Nucleolin)

Beyond the preview

Go deeper on IR780 + PLGA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IR780 + PLGA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call